BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 25621694)

  • 1. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.
    Wu CK; Yang YH; Juang JJ; Wang YC; Tsai CT; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Medicine (Baltimore); 2015 Jan; 94(3):e424. PubMed ID: 25621694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
    Lee HF; See LC; Chan YH; Yeh YH; Wu LS; Liu JR; Tu HT; Wang CL; Kuo CT; Chang SH
    Intern Med J; 2018 Sep; 48(9):1123-1132. PubMed ID: 29808610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prevention of cardiovascular disease events with renin-angiotensin system blockade in autosomal dominant polycystic kidney disease dialysis patients: A nationwide cohort study.
    Lu CL; Lin CY; Lin LY; Chen PC; Zheng CM; Lu KC; Yeih DF
    Medicine (Baltimore); 2021 Jul; 100(26):e26559. PubMed ID: 34190195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Chang TI; Winkelmayer WC
    Nephrol Dial Transplant; 2017 May; 32(5):862-869. PubMed ID: 27190342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.
    Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF; Wetmore JB
    Kidney Blood Press Res; 2016; 41(6):873-885. PubMed ID: 27871075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.
    Chan KE; Ikizler TA; Gamboa JL; Yu C; Hakim RM; Brown NJ
    Kidney Int; 2011 Nov; 80(9):978-985. PubMed ID: 21775975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
    BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Viral Infection in Patients Using Either Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Nationwide Population-based Propensity Score Matching Study.
    Lin SY; Ju SW; Lin CL; Lin CC; Hsu WH; Chou CH; Chi CY; Hsu CY; Kao CH
    Clin Infect Dis; 2020 Dec; 71(10):2695-2701. PubMed ID: 32504531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
    PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
    Hsieh YC; Hung CY; Li CH; Liao YC; Huang JL; Lin CH; Wu TJ
    Medicine (Baltimore); 2016 May; 95(20):e3721. PubMed ID: 27196491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study.
    Voskamp PWM; Dekker FW; van Diepen M; Hoogeveen EK;
    J Am Soc Hypertens; 2017 Oct; 11(10):635-643. PubMed ID: 28802945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
    Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
    Sci Rep; 2015 Nov; 5():17150. PubMed ID: 26612282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer Predialysis ACEi/ARB Utilization Is Associated With Reduced Postdialysis Mortality.
    Gosmanova EO; Molnar MZ; Naseer A; Sumida K; Potukuchi P; Gaipov A; Wall BM; Thomas F; Streja E; Kalantar-Zadeh K; Kovesdy CP
    Am J Med; 2020 Sep; 133(9):1065-1073.e3. PubMed ID: 32330490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.